- CID5721353
-
- $40.00
-
2026-07-27
- CAS:301356-95-6
- Purity: 99.20%
- Supply Ability: 10g
- CID5721353
-
- $1.00
-
2019-12-26
- CAS:301356-95-6
- Min. Order: 1KG
- Purity: 97%-99.9%
- Supply Ability: 100kg
|
| | CID5721353 Basic information |
| Product Name: | CID5721353 | | Synonyms: | CID5721353;CID5721353, BCL6 inhibitor;BCL6 inhibitor(CID5721353);CID5721353 BDL6 inhribitor;CID-5721353;CID 5721353;79-6 (CID5721353， BCL6 inhibitor);CID 5721353;CID-5721353;CID 5721353;2-(5-(5-bromo-2-oxoindolin-3-ylidene)-4-oxo-2-thioxothiazolidin-3-yl)succinic acid | | CAS: | 301356-95-6 | | MF: | C15H9BrN2O6S2 | | MW: | 457.28 | | EINECS: | | | Product Categories: | API | | Mol File: | 301356-95-6.mol |  |
| | CID5721353 Chemical Properties |
| density | 2.06±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | pka | 3.02±0.23(Predicted) | | color | Light brown to brown |
| | CID5721353 Usage And Synthesis |
| Description | CID-5721353 is an inhibitor of the transcriptional repressor B cell lymphoma 6 (Bcl-6; Ki = 147 μM). It is selective for Bcl-6 over Kaiso, hypermethylated in cancer 1 (HIC1), and promyelocytic leukemia zinc finger (PLZF) at 50 μM. CID-5721353 is cytotoxic against Bcl-6-dependent SU-DLH-6, SU-DLH-4, Farage, OCI-LY7, OCI-LY1, and OCI-LY10 diffuse large B cell lymphoma (DLBCL) cells (GI50s = 0.024-0.936 mM) but not Bcl-6-independent Toledo or OCI-LY4 DLBCL cells (GI50 = >15 mM for both). It increases expression of the Bcl-6 target genes ATR, TP53, CD69, p21, and CD44 in SU-DLH-6 and SU-DHL-4 cells when used at a concentration of 50 μM. CID-5721353 (50 mg/kg) reduces tumor growth in OCI-LY7 and SU-DHL-6 mouse xenograft models. | | Uses | CID5721353 is an inhibitor of BCL6 with an IC50 value of 212 μM, which corresponds to a Ki of 147 μM. | | in vivo | In order to test whether CID5721353 (Compound 79-6) can perform as an anti-lymphoma therapeutic agent in vivo, whether it can penetrate tumors after parenteral administration through a distal site is determined. For this purpose 107OCI-Ly7 cells are injected into the right flank of 10 SCID mice and allowed to form tumors. Once tumors reach ~1.5 grams, animals are injected IP with a single dose of 50 mg/kg of CID5721353 in 10% DMSO or vehicle (10% DMSO) and sacrificed at 0.5, 1, 1.5, 3, 6, 12 and 24 hours after CID5721353 administration. Blood and tumors are harvested. Quantitative HPLC/MS analysis of the serum shows that CID5721353 levels peak (to 55 μg/mL, which is equivalent to a 122 μM concentration) one hour after the IP injection. CID5721353 also reaches its highest peak (24.5 ng/mg) at the 1-hour time point in the tumors, and after a sharp decline in levels, decreases gradually over 24 hours[1]. | | References | [1] Cerchietti LC, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010 Apr 13;17(4):400-11. DOI:10.1016/j.ccr.2009.12.050 |
| | CID5721353 Preparation Products And Raw materials |
|